Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥50% reduction in high-risk patients: Results from VOYAGER

Björn W. Karlson, Stephen J. Nicholls, Pia Lundman, Mike K. Palmer, Philip J. Barter

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: Guidelines published in 2011 by the European Atherosclerosis Society and the European Society of Cardiology recommend a goal of either low-density lipoprotein cholesterol (LDL-C) <70 mg/dl (∼1.8 mmol/l) or ≥50% reduction in LDL-C for patients at very high cardiovascular risk. The aim of this study was to determine the percentage of high-risk patients from the VOYAGER individual patient data meta-analysis treated with rosuvastatin 10-40 mg, atorvastatin 10-80 mg or simvastatin 10-80 mg who achieved this goal. Methods: We analysed 25,075 patient exposures from high-risk patients. Paired comparisons were made between each rosuvastatin dose and an equal or higher dose of either atorvastatin or simvastatin, with a series of meta-analyses that included only randomised studies that directly compared rosuvastatin and its comparator treatments. Results: As statin dose increased, higher percentages of patients achieved LDL-C <70 mg/dl or ≥50% LDL-C reduction. A greater percentage achieved this goal with rosuvastatin 10-40 mg (43.8-79.0%) than with equal or double milligram doses of atorvastatin (16.1-65.2%) or simvastatin (0-39.7%).Paired comparisons showed statistically significant differences for: rosuvastatin 10 mg vs. atorvastatin 10-20 mg and simvastatin 10-20 mg; rosuvastatin 20 mg vs. atorvastatin 20-40 mg and simvastatin 20-80 mg; and rosuvastatin 40 mg vs. atorvastatin 40-80 mg and simvastatin 40-80 mg (all p < 0.001). Conclusion: These data from VOYAGER highlight the importance of an effective statin at an appropriate dose to achieve treatment goals for LDL-C in patients with very high cardiovascular risk.

LanguageEnglish
Pages265-269
Number of pages5
JournalAtherosclerosis
Volume228
Issue number1
DOIs
Publication statusPublished - 1 May 2013

Keywords

  • Atorvastatin
  • Guidelines
  • Low-density lipoprotein cholesterol
  • Meta-analysis
  • Rosuvastatin
  • Simvastatin
  • Targets

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Karlson, Björn W. ; Nicholls, Stephen J. ; Lundman, Pia ; Palmer, Mike K. ; Barter, Philip J. / Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥50% reduction in high-risk patients : Results from VOYAGER. In: Atherosclerosis. 2013 ; Vol. 228, No. 1. pp. 265-269.
@article{0211b4b3d66e4ed9a071efa818189ea9,
title = "Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥50{\%} reduction in high-risk patients: Results from VOYAGER",
abstract = "Objective: Guidelines published in 2011 by the European Atherosclerosis Society and the European Society of Cardiology recommend a goal of either low-density lipoprotein cholesterol (LDL-C) <70 mg/dl (∼1.8 mmol/l) or ≥50{\%} reduction in LDL-C for patients at very high cardiovascular risk. The aim of this study was to determine the percentage of high-risk patients from the VOYAGER individual patient data meta-analysis treated with rosuvastatin 10-40 mg, atorvastatin 10-80 mg or simvastatin 10-80 mg who achieved this goal. Methods: We analysed 25,075 patient exposures from high-risk patients. Paired comparisons were made between each rosuvastatin dose and an equal or higher dose of either atorvastatin or simvastatin, with a series of meta-analyses that included only randomised studies that directly compared rosuvastatin and its comparator treatments. Results: As statin dose increased, higher percentages of patients achieved LDL-C <70 mg/dl or ≥50{\%} LDL-C reduction. A greater percentage achieved this goal with rosuvastatin 10-40 mg (43.8-79.0{\%}) than with equal or double milligram doses of atorvastatin (16.1-65.2{\%}) or simvastatin (0-39.7{\%}).Paired comparisons showed statistically significant differences for: rosuvastatin 10 mg vs. atorvastatin 10-20 mg and simvastatin 10-20 mg; rosuvastatin 20 mg vs. atorvastatin 20-40 mg and simvastatin 20-80 mg; and rosuvastatin 40 mg vs. atorvastatin 40-80 mg and simvastatin 40-80 mg (all p < 0.001). Conclusion: These data from VOYAGER highlight the importance of an effective statin at an appropriate dose to achieve treatment goals for LDL-C in patients with very high cardiovascular risk.",
keywords = "Atorvastatin, Guidelines, Low-density lipoprotein cholesterol, Meta-analysis, Rosuvastatin, Simvastatin, Targets",
author = "Karlson, {Bj{\"o}rn W.} and Nicholls, {Stephen J.} and Pia Lundman and Palmer, {Mike K.} and Barter, {Philip J.}",
year = "2013",
month = "5",
day = "1",
doi = "10.1016/j.atherosclerosis.2013.02.027",
language = "English",
volume = "228",
pages = "265--269",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥50% reduction in high-risk patients : Results from VOYAGER. / Karlson, Björn W.; Nicholls, Stephen J.; Lundman, Pia; Palmer, Mike K.; Barter, Philip J.

In: Atherosclerosis, Vol. 228, No. 1, 01.05.2013, p. 265-269.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥50% reduction in high-risk patients

T2 - Atherosclerosis

AU - Karlson, Björn W.

AU - Nicholls, Stephen J.

AU - Lundman, Pia

AU - Palmer, Mike K.

AU - Barter, Philip J.

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Objective: Guidelines published in 2011 by the European Atherosclerosis Society and the European Society of Cardiology recommend a goal of either low-density lipoprotein cholesterol (LDL-C) <70 mg/dl (∼1.8 mmol/l) or ≥50% reduction in LDL-C for patients at very high cardiovascular risk. The aim of this study was to determine the percentage of high-risk patients from the VOYAGER individual patient data meta-analysis treated with rosuvastatin 10-40 mg, atorvastatin 10-80 mg or simvastatin 10-80 mg who achieved this goal. Methods: We analysed 25,075 patient exposures from high-risk patients. Paired comparisons were made between each rosuvastatin dose and an equal or higher dose of either atorvastatin or simvastatin, with a series of meta-analyses that included only randomised studies that directly compared rosuvastatin and its comparator treatments. Results: As statin dose increased, higher percentages of patients achieved LDL-C <70 mg/dl or ≥50% LDL-C reduction. A greater percentage achieved this goal with rosuvastatin 10-40 mg (43.8-79.0%) than with equal or double milligram doses of atorvastatin (16.1-65.2%) or simvastatin (0-39.7%).Paired comparisons showed statistically significant differences for: rosuvastatin 10 mg vs. atorvastatin 10-20 mg and simvastatin 10-20 mg; rosuvastatin 20 mg vs. atorvastatin 20-40 mg and simvastatin 20-80 mg; and rosuvastatin 40 mg vs. atorvastatin 40-80 mg and simvastatin 40-80 mg (all p < 0.001). Conclusion: These data from VOYAGER highlight the importance of an effective statin at an appropriate dose to achieve treatment goals for LDL-C in patients with very high cardiovascular risk.

AB - Objective: Guidelines published in 2011 by the European Atherosclerosis Society and the European Society of Cardiology recommend a goal of either low-density lipoprotein cholesterol (LDL-C) <70 mg/dl (∼1.8 mmol/l) or ≥50% reduction in LDL-C for patients at very high cardiovascular risk. The aim of this study was to determine the percentage of high-risk patients from the VOYAGER individual patient data meta-analysis treated with rosuvastatin 10-40 mg, atorvastatin 10-80 mg or simvastatin 10-80 mg who achieved this goal. Methods: We analysed 25,075 patient exposures from high-risk patients. Paired comparisons were made between each rosuvastatin dose and an equal or higher dose of either atorvastatin or simvastatin, with a series of meta-analyses that included only randomised studies that directly compared rosuvastatin and its comparator treatments. Results: As statin dose increased, higher percentages of patients achieved LDL-C <70 mg/dl or ≥50% LDL-C reduction. A greater percentage achieved this goal with rosuvastatin 10-40 mg (43.8-79.0%) than with equal or double milligram doses of atorvastatin (16.1-65.2%) or simvastatin (0-39.7%).Paired comparisons showed statistically significant differences for: rosuvastatin 10 mg vs. atorvastatin 10-20 mg and simvastatin 10-20 mg; rosuvastatin 20 mg vs. atorvastatin 20-40 mg and simvastatin 20-80 mg; and rosuvastatin 40 mg vs. atorvastatin 40-80 mg and simvastatin 40-80 mg (all p < 0.001). Conclusion: These data from VOYAGER highlight the importance of an effective statin at an appropriate dose to achieve treatment goals for LDL-C in patients with very high cardiovascular risk.

KW - Atorvastatin

KW - Guidelines

KW - Low-density lipoprotein cholesterol

KW - Meta-analysis

KW - Rosuvastatin

KW - Simvastatin

KW - Targets

UR - http://www.scopus.com/inward/record.url?scp=84876805989&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2013.02.027

DO - 10.1016/j.atherosclerosis.2013.02.027

M3 - Article

VL - 228

SP - 265

EP - 269

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -